Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Gets Price Target Cut from Royal Bank Of Canada

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price decreased by Royal Bank Of Canada from $299.00 to $296.00 in a research note issued to investors on Thursday, Marketbeat Ratings reports. Royal Bank Of Canada currently has an outperform rating on the specialty pharmaceutical company’s stock.

A number of other research analysts have also commented on the stock. Stifel Nicolaus set a $275.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 4th. Needham & Company LLC increased their price target on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, August 26th. Wells Fargo & Company increased their price target on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Citigroup initiated coverage on Jazz Pharmaceuticals in a research report on Wednesday, September 30th. They set a “buy” rating and a $325.00 price target on the stock. Finally, TD Cowen boosted their price objective on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $291.25.

Jazz Pharmaceuticals Stock Down 1.8%

Shares of Jazz Pharmaceuticals stock opened at $218.42 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.78 and a quick ratio of 1.58. Jazz Pharmaceuticals has a 1-year low of $128.80 and a 1-year high of $266.38. The business’s fifty day moving average price is $244.27 and its two-hundred day moving average price is $231.00. The company has a market capitalization of $14.18 billion, a P/E ratio of 15.06, a PEG ratio of 0.20 and a beta of 0.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.18 by ($0.47). The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The company’s revenue for the quarter was up 15.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($8.25) EPS. As a group, research analysts forecast that Jazz Pharmaceuticals will post 21.59 EPS for the current year.

Insider Activity at Jazz Pharmaceuticals

In related news, EVP Neena Patil sold 1,200 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total transaction of $289,128.00. Following the transaction, the executive vice president directly owned 47,671 shares of the company’s stock, valued at approximately $11,485,850.74. The trade was a 2.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $230.33, for a total transaction of $1,381,980.00. Following the sale, the director directly owned 345,875 shares of the company’s stock, valued at $79,665,388.75. This trade represents a 1.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 100,121 shares of company stock valued at $24,855,802 over the last ninety days. 4.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. ANB Bank bought a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter worth about $215,000. GK Wealth Management LLC acquired a new stake in shares of Jazz Pharmaceuticals in the third quarter worth $85,000. Balefire LLC bought a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter worth $226,000. Wedmont Private Capital boosted its holdings in shares of Jazz Pharmaceuticals by 23.8% during the 3rd quarter. Wedmont Private Capital now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $681,000 after buying an additional 588 shares during the period. Finally, GAMMA Investing LLC grew its stake in Jazz Pharmaceuticals by 15.9% in the 3rd quarter. GAMMA Investing LLC now owns 1,631 shares of the specialty pharmaceutical company’s stock valued at $378,000 after buying an additional 224 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: BofA Securities raised its price target for Jazz Pharmaceuticals (JAZZ) to $313 from $307 while maintaining a Buy rating, signaling continued confidence in the company’s outlook. BofA Securities Adjusts Jazz Pharmaceuticals Price Target
• Positive Sentiment: CNBC commentator Jim Cramer expressed support for Jazz Pharmaceuticals, adding favorable investor sentiment around the stock. Cramer’s Lightning Round: Jazz Pharmaceuticals
• Positive Sentiment: Truist raised its price target to $286, reinforcing a constructive view of JAZZ’s valuation and prospects. Truist Raises Jazz Pharmaceuticals Price Target
• Neutral Sentiment: Chief Commercial Officer Samantha Pearce will retire by June 30, 2027. The planned timing provides a transition period, but investors may monitor execution and the search for a successor. Samantha Pearce Retirement Announcement
• Neutral Sentiment: RBC trimmed its price target to $296 from $299 but retained an Outperform rating, leaving its fundamental stance positive despite the modest valuation adjustment. RBC Trims Jazz Pharmaceuticals Price Target
• Negative Sentiment: CEO Renee Gala sold 2,000 shares worth approximately $472,800. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, reducing its negative significance, though insider selling can still weigh on sentiment. Jazz Pharmaceuticals CEO Stock Sale

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious neurological and oncology-related conditions. Founded in 2003 and headquartered in Dublin, Ireland, the company operates internationally, with a significant commercial presence in the United States and other markets.

Jazz’s neuroscience portfolio includes Xywav and Xyrem, which contain oxybate and are used to treat narcolepsy-related symptoms; Xywav is also approved for idiopathic hypersomnia in adults.